SCHEMBL10116709

SCHEMBL10116709

CC(C)S(=O)(=O)Nc1ccc(C(=O)Nc2ccc(C(=O)NC(C)(C)C)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.53
KDM4E B2RXH2 3/20 0.53
GRIA4 P48058 2/20 0.47
GRIA2 P42262 1/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
NR1H4 Q96RI1 2/20 0.46
EPHX2 P34913 1/20 0.46
MAPT P10636 3/20 0.46
HDAC3 O15379 1/20 0.46
HDAC11 Q96DB2 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
PRKAB2 O43741 1/20 0.45
PRKAG1 P54619 1/20 0.45
PRKAA2 P54646 1/20 0.45
PRKAA1 Q13131 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10116467 0.87 MEN1 (0.62) LMNAKDM4EMEN1KMT2ACA1
SCHEMBL10116514 0.86 KDM4E (0.53) LMNAKDM4EGRIA4GRIA2MEN1
SCHEMBL10116522 0.86 KDM4E (0.53) LMNAKDM4EGRIA4GRIA2MEN1
SCHEMBL10116526 0.84 KDM4E (0.74) LMNAKDM4EGRIA4GRIA2MEN1
SCHEMBL10116460 0.84 NPC1 (0.67) LMNAKDM4EGRIA4GRIA2MEN1
SCHEMBL10116458 0.84 GRIA4 (0.60) LMNAKDM4EGRIA4GRIA2MEN1
SCHEMBL10116572 0.83 TRPV1 (0.62) LMNAKDM4ENPSR1MAPTHDAC3
SCHEMBL17090506 0.83 NR1H4 (0.47) LMNACA1CA2NR1H4EPHX2
SCHEMBL10116397 0.83 KMT2A (0.49) LMNAKDM4EMEN1KMT2ACA1
SCHEMBL10116464 0.83 LMNA (0.76) LMNAKDM4EGRIA4GRIA2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R LMNA 1925/4885KDM4E 1668/4885GRIA4 371/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R LMNA 2068/4885KDM4E 1627/4885GRIA4 335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.